{
    "2018-05-29": [
        [
            {
                "time": "2018-11-01",
                "original_text": "Novo Nordisk's oral diabetes drug beats Jardiance in study",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "oral diabetes drug",
                        "beats",
                        "Jardiance",
                        "study"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-30",
                "original_text": "Analyzing Incyte’s Revenue Stream in Q1 2018",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Revenue Stream",
                        "Q1 2018"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-15",
                "original_text": "An Overview Merck’s Diabetes and Women’s Health Portfolios",
                "features": {
                    "keywords": [
                        "Merck",
                        "Diabetes",
                        "Women’s Health",
                        "Portfolios"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-30",
                "original_text": "Incyte’s Revenue Trend in Q1 2018",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Revenue Trend",
                        "Q1 2018"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}